Operating CF
$713M
Capex
-$71.6M
Free Cash Flow
$641M
FCF Margin
+90.0%
Cash flow waterfall for Alnylam Pharmaceuticals (ALNY) — TTM through Q1 2026
Free cash flow: $641M
Note: Other Investing is large — driven mainly by purchases or sales of investments.
Cash flow breakdown for Alnylam Pharmaceuticals (ALNY) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $713M | $713M |
| Capital Expenditure | -$71.6M | $641M |
| Free Cash Flow | $641M | $641M |
| Other Investing | $369M | $1.01B |
| Net Debt Change | -$553M | $457M |
| Other Financing | $219M | $676M |
| Forex Effect | $13.8M | $690M |
| Net Cash Increase | $690M | $690M |
- Operating Cash Flow$713M
- Capital Expenditure-$71.6M
- Free Cash Flow$641M
- Other Investing$369M
- Net Debt Change-$553M
- Other Financing$219M
- Forex Effect$13.8M
- Net Cash Increase$690M
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Forecast & Valuation
Operations
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement
Capital Return
How this company returns cash to shareholders — buybacks, dividends, and stock splits.